MCM, LabCorp Expand Access to Global Central Lab Services

Mitsubishi Chemical Medience Corp. (MCM) has signed a Master Service Agreement with the clinical trials division of Laboratory Corporation of America that allows LabCorp Clinical Trials and MCM to extend their service offerings to clients in Japan and around the world, respectfully.
 
“Pharmaceutical sponsors everywhere continue to look to new markets and technologies for drug development opportunities, and our clients are no different,” said Mr. Shinichi Yoshihara, president and chief executive officer of Mitsubishi Chemical Medience Corp. “We are therefore excited to work closely with LabCorp as a global leader in central lab, biomarker and specialty testing, and with cutting-edge technologies from both sides we are confident this partnership will provide new channels of growth and competitive advantage for both companies.”
 
“MCM is a leading diagnostic laboratory and central lab in Japan with considerable experience and long-standing relationships in the medical and pharmaceutical communities,” said Dr. Mark Brecher, LabCorp’s chief medical officer. “The two companies complement each other in this respect, and we look forward to working together to offer a complete global solution for our customers conducting trials in Japan and around the globe.”